NCT02599532View on ClinicalTrials.gov

Pharmacokinetics of Apixaban in Nephrotic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2017

Primary Completion Date

June 28, 2019

Study Completion Date

June 28, 2019

Conditions
Nephrotic SyndromeProteinuria
Interventions
DRUG

apixaban

Study subjects will be given a single-dose of apixaban 10 mg.

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

North Carolina Translational and Clinical Sciences Institute

OTHER

lead

University of North Carolina, Chapel Hill

OTHER

NCT02599532 - Pharmacokinetics of Apixaban in Nephrotic Syndrome | Biotech Hunter | Biotech Hunter